Video

Customizing Imaging Based on Calcitonin Levels in MTC

For High-Definition, Click

The role of imaging before surgery for patients with medullary thyroid cancer relies heavily on the initial calcitonin level. Additionally, this level can be used to suggest prognosis and an appropriate surgical procedure.

In some cases, believes Eric J. Sherman, MD, imaging can be reserved until after surgery. However, utilizing imaging before surgery helps determine nodal involvement, distribution, and the presence of mediastinal disease, notes Lori J. Wirth, MD. Ultrasounds are often utilized before surgery but often miss high retropharyngeal, deep paratracheal, and mediastinal lymph node involvement.

The decision concerning whether to utilize ultrasound, CT, or MRI can be guided by the calcitonin level, explains R. Michael Tuttle, MD. If levels are 30 or 40 with a small nodule, imaging may not be necessary. However, if levels are in the hundreds, lymph node involvement is more likely, requiring a CT scan or MRI of the neck and chest to ensure the proper surgical procedure is performed. Steven I. Sherman, MD, adds that if the calcitonin level is around 500, cross-sectional imaging of the neck, chest, and liver should be performed prior to surgery to diagnose distant disease.

In addition to staging, calcitonin levels may help indicate prognosis and whether a cure is possible, remarks Tuttle. If levels are 3,000 to 5,000 a biochemical cure is unlikely. In these situations, it may be appropriate to bypass a surgery, to avoid unneeded comorbidities.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity